Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10207211 | 1.00 | HTR2A (0.52) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL172237 | 1.00 | HTR2A (0.52) | HTR2AHRH1PGRADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL4356665 | 0.97 | HTR2A (0.50) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL9764180 | 0.89 | HTR2A (0.44) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL3200413 | 0.85 | HTR2A (0.41) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL10064563 | 0.85 | ADRA2A (0.41) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL7904494 | 0.85 | HTR2A (0.41) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL17636225 | 0.85 | ADRA2A (0.41) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL27277859 | 0.84 | HTR2A (0.40) | HTR2AHRH1PGRADRA2AADRA2B | |
| SCHEMBL10207192 | 0.82 | PGR (0.39) | HTR2AHRH1PGRADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| CN-116469621-B | Production process of ultrathin transposed conductor | 沈阳宏远电磁线股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116469621-A | Production process of ultrathin transposed conductor | 沈阳宏远电磁线股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| US-4112078-A | ACYLATION, REDUCTION, ZOAPATLE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | disclosed |
| US-20260028375-A1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | ETH ZUERICH (CH) | 2026-01-29 | — | — | US | disclosed |
| US-12522647-B2 | Beta-arrestin mutants | PAUL SCHERRER INSTITUT (CH) | 2026-01-13 | — | — | US | disclosed |
| US-12410213-B2 | Polypeptides self-assembling into nanoparticles | ETH ZËRICH (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-3833676-B1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | ETH ZUERICH (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-112533938-B | Polypeptides self-assembled into nanoparticles | 苏黎世联邦理工学院 | 2025-04-25 | — | — | CN | disclosed |
| EP-0148883-B1 | ALLOPURINOL PRODRUGS | A/S GEA Farmaceutisk Fabrik (DK) | 1990-02-14 | — | — | EP | disclosed |
| US-4694006-A | Acyl- or acyloxymethyl-allopurinol prodrugs | A/S GEA (DK) | 1987-09-15 | — | — | US | disclosed |
| EP-0206621-A1 | Process for disproportionating silanes | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1986-12-30 | — | — | EP | disclosed |
| US-4543216-A | REACTING A VINYL BENZYL HALIDE WITH AN AMINO ACID OR AMINO SULFONIC ACID | NIPPON PAINT CO., LTD. (JP) | 1985-09-24 | — | — | US | disclosed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | disclosed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | disclosed |
| US-4452746-A | TO MODIFY PROPERTIES OF HIGH MOLECULAR WEIGHT COMPOUNDS | NIPPON PAINT CO., LTD. (JP) | 1984-06-05 | — | — | US | disclosed |
| US-3954845-A | Synthetic detergents of the ampholytic betaine type, process for preparing the same and compositions | MODOKEMI AKTIEBOLAG (SW) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028375-A1 | POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES | PHAX, TPX2, MLX | HTR2A 2841/4885HRH1 1574/4885PGR 4751/4885 |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | HTR2A 2669/4885HRH1 1996/4885PGR 3289/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | HTR2A 4372/4885HRH1 546/4885PGR 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.